<p>Hantz Financial Services Inc. 在最近向證券交易委員會提交的文件中表示，在第四季度收購了 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - 免費報告) 的新股份。該公司收購了 7,827 股生物技術公司的股票，價值約為 839,000 美元。</p>
<p>獲取 <strong>Ligand Pharmaceuticals</strong> 的提醒：</p>
<p>其他幾家大型投資者最近也增加或減少了對該公司的持股。State Street Corp 在第三季度將其在 Ligand Pharmaceuticals 的持股提高了 2.7%。State Street Corp 目前擁有 707,414 股生物技術公司的股票，價值 70,805,000 美元，此前在上個季度又收購了 18,642 股。Congress Asset Management Co. 在第三季度將其在 Ligand Pharmaceuticals 的持股提高了 3.0%。Congress Asset Management Co. 目前擁有 604,038 股生物技術公司的股票，價值 60,458,000 美元，此前在上個季度又購買了 17,414 股。Chicago Capital LLC 在第三季度將其在 Ligand Pharmaceuticals 的持股提高了 6.0%。Chicago Capital LLC 目前擁有 545,821 股生物技術公司的股票，價值 54,631,000 美元，此前在上個季度又購買了 30,875 股。Geode Capital Management LLC 在第三季度將其在 Ligand Pharmaceuticals 的持股提高了 5.5%。Geode Capital Management LLC 目前擁有 428,270 股生物技術公司的股票，價值 42,874,000 美元，此前在上個季度又購買了 22,495 股。最後，Loomis Sayles &amp; Co. L P 在第三季度將其在 Ligand Pharmaceuticals 的持股提高了 44.3%。Loomis Sayles &amp; Co. L P 目前擁有 372,779 股生物技術公司的股票，價值 37,312,000 美元，此前在上個季度又購買了 114,436 股。機構投資者持有該公司 91.28% 的股票。</p>
<h2>華爾街分析師觀點</h2>
<p>一些研究分析師最近對該公司進行了評論。加拿大皇家銀行在 12 月 11 日的研究報告中將 Ligand Pharmaceuticals 的目標價格從 141.00 美元提高至 143.00 美元，並給予該公司 “跑贏大盤” 的評級。Benchmark 在 12 月 23 日的研究報告中重申了 “買入” 評級，並設定了 135.00 美元的目標價格。巴克萊在 12 月 16 日的研究報告中將 Ligand Pharmaceuticals 的目標價格從 150.00 美元提高至 160.00 美元，並給予該股票 “增持” 評級。Oppenheimer 在 11 月 8 日的研究報告中將 Ligand Pharmaceuticals 的目標價格從 135.00 美元提高至 147.00 美元，並給予該股票 “跑贏大盤” 的評級。最後，HC Wainwright 在 12 月 11 日的研究報告中重申了對 Ligand Pharmaceuticals 的 “買入” 評級。根據 MarketBeat.com 的數據，六位研究分析師對該股票給予了買入評級，Ligand Pharmaceuticals 的平均評級為 “買入”，共識目標價格為 147.00 美元。</p>
<p><strong>閲讀我們關於 Ligand Pharmaceuticals 的最新研究報告</strong></p>
<h2>Ligand Pharmaceuticals 的內部活動</h2>
<p>在其他 Ligand Pharmaceuticals 的新聞中，董事 John L. Lamattina 於 11 月 27 日星期三出售了 2,406 股公司的股票。該股票以平均價格 123.65 美元出售，總交易額為 297,501.90 美元。交易完成後，該董事目前擁有 29,515 股公司的股票，價值 3,649,529.75 美元。這代表其持股減少了 7.54%。該交易已在向 SEC 提交的文件中披露，相關文件可在 SEC 網站上找到。此外，首席財務官 Octavio Espinoza 於 12 月 23 日星期一出售了 2,104 股 Ligand Pharmaceuticals 的股票。該股票以平均價格 116.37 美元出售，總價值為 244,842.48 美元。交易完成後，首席財務官目前在公司擁有 20,647 股，價值約為 2,402,691.39 美元。這代表其持股減少了 9.25%。該銷售的披露信息可以在這裏找到。公司內部人士目前持有 5.90% 的股票。</p>
<h2>Ligand Pharmaceuticals 股票表現</h2>
<p>LGND 股票在週五開盤價為 116.55 美元。該公司的市值為 22 億美元，市盈率為 46.43，貝塔值為 1.05。Ligand Pharmaceuticals Incorporated 的 52 周低點為 67.72 美元，52 周高點為 129.90 美元。該股票的 50 日移動平均價格為 115.13 美元，200 日移動平均價格為 109.02 美元。</p>
<h2>關於 Ligand Pharmaceuticals</h2>
<p>(免費報告)</p>
<p>Ligand Pharmaceuticals Incorporated 是一家生物製藥公司，致力於全球生物製藥資產的開發和許可。其商業項目包括用於治療多發性骨髓瘤的 Kyprolis 和 Evomela；用於治療急性淋巴細胞白血病或成人和兒童患者淋巴母細胞淋巴瘤的重組厄爾文酶 Rylaze；用於罕見腎病的雙重內皮素和血管緊張素 II 受體拮抗劑 Filspari；用於骨質疏鬆症的特立帕肽注射產品；用於預防由肺炎鏈球菌血清型引起的侵襲性疾病的 Vaxneuvance；以及幫助抵禦兒童肺炎球菌肺炎的肺炎球菌結合疫苗 Pneumosil。</p>
<h2>精選文章</h2>
<ul>
<li>我們更喜歡的五隻股票比 Ligand Pharmaceuticals 更好</li>
<li>消費品股票解析</li>
<li>Nebius Group：市場過度反應還是真正的 AI 顛覆？</li>
<li>股票交易術語 - 每位投資者需要了解的股票術語</li>
<li>投資黃金的最佳方式是...</li>
<li>在 P&amp;G 創下新高之前買入</li>
<li>為什麼 Nike 股票可能是 2025 年的最佳反彈股</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEdORA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEdORA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Ligand 製藥嗎？</h2>
<p>在考慮 Ligand 製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Ligand 製藥並不在名單上。</p>
<p>雖然 Ligand 製藥目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Ligand制藥

<p>Hantz Financial Services Inc. 在 Ligand Pharmaceuticals (NASDAQ:LGND) 中獲得了約 839,000 美元的新頭寸，購買了 7,827 股。其他機構投資者也增加了在 Ligand 的持股，State Street Corp 和 Congress Asset Management Co. 提高了他們的持股比例。分析師對 Ligand 給出了共識 “買入” 評級，目標價格範圍在 135 美元到 160 美元之間。最近的內部交易包括董事 John L. Lamattina 和首席財務官 Octavio Espinoza 的股票出售。Ligand 的股票開盤價為 116.55 美元，市值為 22 億美元</p>

<p>Hantz Financial Services Inc. acquired a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The firm acquired 7,827 shares of the biotechnology company's stock, valued at approximately $839,000.</p>
<div class="lb-trans"><p>Hantz Financial Services Inc. 在最近向證券交易委員會提交的文件中表示，在第四季度收購了 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - 免費報告) 的新股份。該公司收購了 7,827 股生物技術公司的股票，價值約為 839,000 美元。</p>
</div><p>Get <strong>Ligand Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Ligand Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other large investors also recently added to or reduced their stakes in the business. State Street Corp raised its holdings in shares of Ligand Pharmaceuticals by 2.7% in the 3rd quarter. State Street Corp now owns 707,414 shares of the biotechnology company's stock valued at $70,805,000 after acquiring an additional 18,642 shares in the last quarter. Congress Asset Management Co. raised its stake in Ligand Pharmaceuticals by 3.0% in the third quarter. Congress Asset Management Co. now owns 604,038 shares of the biotechnology company's stock valued at $60,458,000 after purchasing an additional 17,414 shares in the last quarter. Chicago Capital LLC lifted its position in Ligand Pharmaceuticals by 6.0% during the third quarter. Chicago Capital LLC now owns 545,821 shares of the biotechnology company's stock valued at $54,631,000 after purchasing an additional 30,875 shares during the last quarter. Geode Capital Management LLC grew its stake in Ligand Pharmaceuticals by 5.5% in the 3rd quarter. Geode Capital Management LLC now owns 428,270 shares of the biotechnology company's stock worth $42,874,000 after buying an additional 22,495 shares in the last quarter. Finally, Loomis Sayles &amp; Co. L P increased its holdings in shares of Ligand Pharmaceuticals by 44.3% in the 3rd quarter. Loomis Sayles &amp; Co. L P now owns 372,779 shares of the biotechnology company's stock worth $37,312,000 after buying an additional 114,436 shares during the last quarter. Institutional investors own 91.28% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家大型投資者最近也增加或減少了對該公司的持股。State Street Corp 在第三季度將其在 Ligand Pharmaceuticals 的持股提高了 2.7%。State Street Corp 目前擁有 707,414 股生物技術公司的股票，價值 70,805,000 美元，此前在上個季度又收購了 18,642 股。Congress Asset Management Co. 在第三季度將其在 Ligand Pharmaceuticals 的持股提高了 3.0%。Congress Asset Management Co. 目前擁有 604,038 股生物技術公司的股票，價值 60,458,000 美元，此前在上個季度又購買了 17,414 股。Chicago Capital LLC 在第三季度將其在 Ligand Pharmaceuticals 的持股提高了 6.0%。Chicago Capital LLC 目前擁有 545,821 股生物技術公司的股票，價值 54,631,000 美元，此前在上個季度又購買了 30,875 股。Geode Capital Management LLC 在第三季度將其在 Ligand Pharmaceuticals 的持股提高了 5.5%。Geode Capital Management LLC 目前擁有 428,270 股生物技術公司的股票，價值 42,874,000 美元，此前在上個季度又購買了 22,495 股。最後，Loomis Sayles &amp; Co. L P 在第三季度將其在 Ligand Pharmaceuticals 的持股提高了 44.3%。Loomis Sayles &amp; Co. L P 目前擁有 372,779 股生物技術公司的股票，價值 37,312,000 美元，此前在上個季度又購買了 114,436 股。機構投資者持有該公司 91.28% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of research analysts recently commented on the company. Royal Bank of Canada increased their target price on Ligand Pharmaceuticals from $141.00 to $143.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, December 11th. Benchmark reiterated a &#34;buy&#34; rating and set a $135.00 price objective on shares of Ligand Pharmaceuticals in a research report on Monday, December 23rd. Barclays boosted their target price on Ligand Pharmaceuticals from $150.00 to $160.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, December 16th. Oppenheimer lifted their price target on shares of Ligand Pharmaceuticals from $135.00 to $147.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, November 8th. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating on shares of Ligand Pharmaceuticals in a research note on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Ligand Pharmaceuticals has an average rating of &#34;Buy&#34; and a consensus price target of $147.00.</p>
<div class="lb-trans"><p>一些研究分析師最近對該公司進行了評論。加拿大皇家銀行在 12 月 11 日的研究報告中將 Ligand Pharmaceuticals 的目標價格從 141.00 美元提高至 143.00 美元，並給予該公司 “跑贏大盤” 的評級。Benchmark 在 12 月 23 日的研究報告中重申了 “買入” 評級，並設定了 135.00 美元的目標價格。巴克萊在 12 月 16 日的研究報告中將 Ligand Pharmaceuticals 的目標價格從 150.00 美元提高至 160.00 美元，並給予該股票 “增持” 評級。Oppenheimer 在 11 月 8 日的研究報告中將 Ligand Pharmaceuticals 的目標價格從 135.00 美元提高至 147.00 美元，並給予該股票 “跑贏大盤” 的評級。最後，HC Wainwright 在 12 月 11 日的研究報告中重申了對 Ligand Pharmaceuticals 的 “買入” 評級。根據 MarketBeat.com 的數據，六位研究分析師對該股票給予了買入評級，Ligand Pharmaceuticals 的平均評級為 “買入”，共識目標價格為 147.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on Ligand Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Ligand Pharmaceuticals 的最新研究報告</strong></p>
</div><h2>Insider Activity at Ligand Pharmaceuticals</h2>
<div class="lb-trans"><h2>Ligand Pharmaceuticals 的內部活動</h2>
</div><p>In other Ligand Pharmaceuticals news, Director John L. Lamattina sold 2,406 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $123.65, for a total transaction of $297,501.90. Following the completion of the transaction, the director now owns 29,515 shares of the company's stock, valued at $3,649,529.75. This represents a 7.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Octavio Espinoza sold 2,104 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $116.37, for a total value of $244,842.48. Following the completion of the sale, the chief financial officer now owns 20,647 shares in the company, valued at approximately $2,402,691.39. This represents a 9.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Ligand Pharmaceuticals 的新聞中，董事 John L. Lamattina 於 11 月 27 日星期三出售了 2,406 股公司的股票。該股票以平均價格 123.65 美元出售，總交易額為 297,501.90 美元。交易完成後，該董事目前擁有 29,515 股公司的股票，價值 3,649,529.75 美元。這代表其持股減少了 7.54%。該交易已在向 SEC 提交的文件中披露，相關文件可在 SEC 網站上找到。此外，首席財務官 Octavio Espinoza 於 12 月 23 日星期一出售了 2,104 股 Ligand Pharmaceuticals 的股票。該股票以平均價格 116.37 美元出售，總價值為 244,842.48 美元。交易完成後，首席財務官目前在公司擁有 20,647 股，價值約為 2,402,691.39 美元。這代表其持股減少了 9.25%。該銷售的披露信息可以在這裏找到。公司內部人士目前持有 5.90% 的股票。</p>
</div><h2>Ligand Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Ligand Pharmaceuticals 股票表現</h2>
</div><p>Shares of LGND stock opened at $116.55 on Friday. The company has a market capitalization of $2.20 billion, a P/E ratio of 46.43 and a beta of 1.05. Ligand Pharmaceuticals Incorporated has a fifty-two week low of $67.72 and a fifty-two week high of $129.90. The stock has a 50 day moving average price of $115.13 and a two-hundred day moving average price of $109.02.</p>
<div class="lb-trans"><p>LGND 股票在週五開盤價為 116.55 美元。該公司的市值為 22 億美元，市盈率為 46.43，貝塔值為 1.05。Ligand Pharmaceuticals Incorporated 的 52 周低點為 67.72 美元，52 周高點為 129.90 美元。該股票的 50 日移動平均價格為 115.13 美元，200 日移動平均價格為 109.02 美元。</p>
</div><h2>About Ligand Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Ligand Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.</p>
<div class="lb-trans"><p>Ligand Pharmaceuticals Incorporated 是一家生物製藥公司，致力於全球生物製藥資產的開發和許可。其商業項目包括用於治療多發性骨髓瘤的 Kyprolis 和 Evomela；用於治療急性淋巴細胞白血病或成人和兒童患者淋巴母細胞淋巴瘤的重組厄爾文酶 Rylaze；用於罕見腎病的雙重內皮素和血管緊張素 II 受體拮抗劑 Filspari；用於骨質疏鬆症的特立帕肽注射產品；用於預防由肺炎鏈球菌血清型引起的侵襲性疾病的 Vaxneuvance；以及幫助抵禦兒童肺炎球菌肺炎的肺炎球菌結合疫苗 Pneumosil。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Ligand Pharmaceuticals</li>
<li>Consumer Staples Stocks, Explained</li>
<li>Nebius Group: Market Overreaction or Real AI Disruption?</li>
<li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li>
<li>The Best Way to Invest in Gold Is...</li>
<li>Buy P&amp;G Now, Before It Sets A New All-Time High</li>
<li>Why Nike Stock Could Be 2025’s Top Comeback Play</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票比 Ligand Pharmaceuticals 更好</li>
<li>消費品股票解析</li>
<li>Nebius Group：市場過度反應還是真正的 AI 顛覆？</li>
<li>股票交易術語 - 每位投資者需要了解的股票術語</li>
<li>投資黃金的最佳方式是...</li>
<li>在 P&amp;G 創下新高之前買入</li>
<li>為什麼 Nike 股票可能是 2025 年的最佳反彈股</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEdORA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=LGND"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Ligand Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Ligand 製藥嗎？</h2>
</div><p>Before you consider Ligand Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Ligand 製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ligand Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Ligand 製藥並不在名單上。</p>
</div><p>While Ligand Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Ligand 製藥目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

漢茨金融服務公司在 Ligand 製藥公司（納斯達克股票代碼：LGND）持有 83.9 萬美元的頭寸